Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Syed Lateef

Gastroenterology Clermont, FL Medical Doctor

NPI 1194769836 CMS profile 280712

821 Oakley Seaver Dr, Clermont, FL 34711

Open in the dashboard

General payments

$2,516

128 records reported · program years 2019–2023

Research payments

$40,639

Paid to them · 8 records reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$6,397,588 paid to institutions, not to them · program years 2020–2025

Through program year 2023, Syed Lateef of Clermont, FL is reported in the CMS Open Payments database as having received $2,516 across 128 general payments and $40,639 in research payments paid to them. Separately, studies naming them as principal investigator received $6,397,588 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $760 28
2023 Research $146 1
2022 General $437 28
2022 Research $291 1
2021 General $719 35
2021 Research $7,745 4
2020 General $332 21
2020 Research $32,458 2
2019 General $268 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Syed Lateef
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Syed Lateef were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Syed Lateef Gastroenterology median Middle half National median
2019 $268 $417 $126–$1,100 $163
2020 $332 $224 $74–$624 $114
2021 $719 $352 $106–$1,054 $132
2022 $437 $448 $129–$1,270 $149
2023 $760 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $1,031 56 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $580 31 payments
  3. Ironwood Pharmaceuticals, Inc $183 9 payments
  4. Janssen Biotech, Inc. $122 3 payments
  5. Janssen Scientific Affairs, LLC $113 1 payment
  6. Pfizer Inc. $83 4 payments
  7. Intercept Pharmaceuticals, Inc. $78 5 payments
  8. Nestle HealthCare Nutrition Inc. $77 5 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $76 5 payments
  10. Allergan Inc. $60 3 payments
  11. Other $112 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,516 128 payments
Products named General payments · program years 2019–2023
  1. XIFAXAN $567 30 payments
  2. LINZESS Gastroenterology $366 20 payments
  3. CREON $356 21 payments
  4. STELARA $235 4 payments
  5. MAVYRET $228 14 payments
  6. Linzess Gi $163 8 payments
  7. RINVOQ $137 2 payments
  8. PLENVU $130 8 payments
  9. VIBERZI $101 7 payments
  10. TRULANCE $84 6 payments
  11. Other $698 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2023
  1. Eli Lilly and Company $40,639 8 payments

Records

136 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record